Holen Sie sich die Stockscreener-App
34.80
5.07%
1.68
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
How moving averages guide Mineralys Therapeutics Inc. trading2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - Newser
Is Mineralys Therapeutics Inc. affected by consumer sentiment2025 Volume Leaders & Reliable Volume Spike Trade Alerts - خودرو بانک
Is Mineralys Therapeutics Inc. undervalued by DCF analysisWeekly Trend Report & Smart Swing Trading Techniques - خودرو بانک
Mineralys reports positive subgroup data for hypertension drug By Investing.com - Investing.com Canada
Can Mineralys Therapeutics Inc. disrupt its industryJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - خودرو بانک
Is Mineralys Therapeutics Inc. a strong candidate for buy and hold2025 Growth vs Value & Weekly Top Gainers Alerts - خودرو بانک
Jefferies expects Mineralys stock to trade up following AstraZeneca data - MSN
Mineralys surges after late-stage trial data AstraZeneca’s blood pressure drug - MSN
Candlestick signals on Mineralys Therapeutics Inc. stock todayInsider Selling & Weekly Top Gainers Trade List - Newser
How to track smart money flows in Mineralys Therapeutics Inc.Weekly Trend Report & Fast Moving Market Watchlists - Newser
Institutional scanner results for Mineralys Therapeutics Inc.July 2025 EndofMonth & Daily Profit Focused Screening - Newser
Will Mineralys Therapeutics Inc. announce a stock split2025 Geopolitical Influence & AI Based Trade Execution Alerts - خودرو بانک
Mineralys Therapeutics Shares Surge on Promising Drug Trials - TipRanks
How sentiment analysis helps forecast Mineralys Therapeutics Inc.Trade Ideas & Weekly Top Gainers Trade List - Newser
Does Mineralys Therapeutics Inc. stock benefit from AI growthJuly 2025 Sector Moves & Free AI Powered Buy and Sell Recommendations - خودرو بانک
Using RSI to spot recovery in Mineralys Therapeutics Inc.2025 Bull vs Bear & Real-Time Volume Analysis - Newser
Mineralys Therapeutics closes $287.5 million public offering By Investing.com - Investing.com Australia
Mineralys Therapeutics presents subgroup analyses of phase 3 launch-htn trial demonstrating efficacy and safety of lorundrostat in hypertension participants with high unmet medical need - MarketScreener
Short interest data insights for Mineralys Therapeutics Inc.Trade Volume Summary & Accurate Trade Setup Notifications - Newser
Rapafusyn Pharmaceuticals’ $44M raise; CAGE Bio’s atopic dermatitis data - Endpoints News
Mineralys Says Lorundrostat Shows 'Meaningful' Blood Pressure Reductions in Phase 3 Trial - MarketScreener
Mineralys reports positive subgroup data for hypertension drug - Investing.com
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need - The Manila Times
16.9mmHg Blood Pressure Reduction: Mineralys' New Drug Shows Promise for Hard-to-Treat Hypertension Patients - Stock Titan
Chart overlay techniques for tracking Mineralys Therapeutics Inc.Insider Buying & Free Verified High Yield Trade Plans - Newser
Is Mineralys Therapeutics Inc. reversing from oversold territoryJuly 2025 Institutional & Verified Swing Trading Watchlist - Newser
How to interpret RSI for Mineralys Therapeutics Inc. stock2025 Technical Patterns & Risk Managed Investment Signals - Newser
Is Mineralys Therapeutics Inc.’s ROIC above industry average2025 Support & Resistance & Consistent Profit Trading Strategies - khodrobank.com
Mineralys Therapeutics Announces Public Offering of Shares - MSN
Can volume confirm reversal in Mineralys Therapeutics Inc.Weekly Trend Report & Verified Technical Trade Signals - Newser
Mineralys Therapeutics Inc. stock trend forecastTrade Risk Assessment & AI Based Trade Execution Alerts - Newser
Is Mineralys Therapeutics Inc. still worth holding after the dip2025 Technical Overview & Safe Entry Trade Signal Reports - Newser
What recovery options are there for Mineralys Therapeutics Inc.Weekly Trend Report & Community Trade Idea Sharing Platform - Newser
What to do if you’re stuck in Mineralys Therapeutics Inc.2025 Geopolitical Influence & Advanced Swing Trade Entry Plans - Newser
Analyzing Mineralys Therapeutics Inc. with risk reward ratio chartsNew Guidance & Free Technical Pattern Based Buy Signals - Newser
Mineralys Therapeutics Closes $287.5 Million Public Offering to Support Clinical Development of Lorundrostat - Quiver Quantitative
Mineralys Therapeutics closes $287.5 million public offering - Investing.com
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - GlobeNewswire
$287.5M Raised: Hypertension Drug Developer Mineralys Completes Major Public Offering for Clinical Trials - Stock Titan
Using data tools to time your Mineralys Therapeutics Inc. exitJuly 2025 Volume & Free Technical Confirmation Trade Alerts - Newser
Jefferies raises Mineralys Therapeutics stock price target to $26 from $15 - Investing.com Nigeria
What high frequency data says about Mineralys Therapeutics Inc.July 2025 Highlights & Technical Entry and Exit Alerts - Newser
Advanced analytics toolkit walkthrough for Mineralys Therapeutics Inc.July 2025 Selloffs & Verified Trade Idea Suggestions - Newser
Will Mineralys Therapeutics Inc. benefit from AI trends2025 Analyst Calls & Technical Pattern Based Signals - خودرو بانک
Predicting Mineralys Therapeutics Inc. trend using moving averagesEarnings Miss & Real-Time Volume Analysis Alerts - Newser
Live market analysis of Mineralys Therapeutics Inc.Earnings Overview Summary & Real-Time Chart Pattern Alerts - Newser
Order flow analysis tools used on Mineralys Therapeutics Inc.Entry Point & Expert Curated Trade Setup Alerts - Newser
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):